Immunothrombosis has emerged as a dominant pathological process exacerbating morbidity and mortality in acute- and long-COVID-19 infections. The hypercoagulable state is due in part to immune system dysregulation, inflammation and endothelial cell damage, as well as a reduction in defense systems. One defense mechanism in particular is glutathione (GSH), a ubiquitously found antioxidant. Evidence suggests that reduction in GSH increases viral replication, pro-inflammatory cytokine release, and thrombosis, as well as decreases macrophage-mediated fibrin removal. The collection of adverse effects as a result of GSH depletion in states like COVID-19 suggest that GSH depletion is a dominant mechanism of immunothrombosis cascade. We aim to review the current literature on the influence of GSH on COVID-19 immunothrombosis pathogenesis, as well as the beneficial effects of GSH as a novel therapeutic for acute- and long-COVID-19.
CITATION STYLE
Glassman, I., Le, N., Mirhosseini, M., Alcantara, C. A., Asif, A., Goulding, A., … Venketaraman, V. (2023, March 1). The Role of Glutathione in Prevention of COVID-19 Immunothrombosis: A Review. Frontiers in Bioscience - Landmark. IMR Press Limited. https://doi.org/10.31083/j.fbl2803059
Mendeley helps you to discover research relevant for your work.